Variables | Antipyretic; Analgesic; Anti-inflammatory drugs | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Model 1 | Model 2 | Model 3 | Model 4 | |||||||||||||||||
β | SE | t | df | P-Value | β | SE | t | df | P-Value | β | SE | t | df | P-Value | β | SE | t | df | P-Value | |
Intercept | 9.51 | 0.08 | 120.05 | 246 | <.0001 | 12.68 | 0.99 | 12.80 | 246 | <.0001 | 9.23 | 0.27 | 34.53 | 241 | <.0001 | 12.26 | 1.02 | 12.03 | 241 | <.0001 |
Pharmacy characteristics | ||||||||||||||||||||
Sex of pharmacist | ||||||||||||||||||||
Male | 0.64 | 0.13 | 5.00 | 243 | <.0001 | 0.52 | 0.13 | 4.03 | 243 | <.0001 | ||||||||||
Female | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
Age of pharmacist (years) | ||||||||||||||||||||
≤45 | −0.65 | 0.18 | −3.62 | 722 | 0.0003 | −0.66 | 0.18 | −3.65 | 722 | 0.0003 | ||||||||||
46–55 | −0.82 | 0.18 | −4.48 | 722 | <.0001 | −0.82 | 0.18 | −4.45 | 722 | <.0001 | ||||||||||
56–65 | −0.62 | 0.19 | −3.26 | 722 | 0.0012 | −0.59 | 0.19 | −3.07 | 722 | 0.0022 | ||||||||||
≥66 | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
Length of operation | ||||||||||||||||||||
≤12 months | −1.06 | 0.20 | −5.35 | 454 | <.0001 | −1.08 | 0.20 | −5.47 | 454 | <.0001 | ||||||||||
13–24 months | −0.80 | 0.20 | −3.97 | 454 | <.0001 | −0.81 | 0.20 | −4.01 | 454 | <.0001 | ||||||||||
≥25 months | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
Separation of drug prescribing and dispensing | ||||||||||||||||||||
Exception | 3.41 | 0.82 | 4.14 | 93 | <.0001 | 3.19 | 0.82 | 3.88 | 93 | 0.0002 | ||||||||||
Application | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
Period of exclusion for reformed program | ||||||||||||||||||||
≤18 months | −1.05 | 0.98 | −1.07 | 88 | 0.2860 | −0.93 | 0.98 | −0.95 | 88 | 0.3455 | ||||||||||
≥19 months | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
Total drug purchase (10 million KRW) | −0.02 | 0.00 | −25.37 | 16,000 | <.0001 | −0.02 | 0.00 | −25.93 | 16,000 | <.0001 | ||||||||||
Regional characteristics | ||||||||||||||||||||
Region | ||||||||||||||||||||
Metropolitan | −0.53 | 0.16 | −3.22 | 241 | 0.0015 | −0.56 | 0.16 | −3.57 | 241 | 0.0004 | ||||||||||
Non-metropolitan | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
Total number of clinics in regions with pharmacies | ||||||||||||||||||||
≤60 | 0.21 | 0.21 | 1.03 | 241 | 0.3027 | 0.12 | 0.20 | 0.61 | 241 | 0.5431 | ||||||||||
≥61 | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
Total number of pharmacy in regions with pharmacies | ||||||||||||||||||||
≤45 | −0.18 | 0.19 | −0.92 | 241 | 0.3597 | −0.17 | 0.18 | −0.92 | 241 | 0.3574 | ||||||||||
≥46 | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
Average of individual income in regions with pharmacies | ||||||||||||||||||||
≤38 million KRW | 0.47 | 0.17 | 2.73 | 241 | 0.0067 | 0.43 | 0.16 | 2.63 | 241 | 0.0091 | ||||||||||
≥39 million KRW | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
Proportion of national basic livelihood security beneficiaries in regions with pharmacies | 0.07 | 0.06 | 1.21 | 241 | 0.2271 | 0.14 | 0.05 | 2.72 | 241 | 0.0070 | ||||||||||
Random parta | Variance | SE | Z | P-Value | Variance | SE | Z | P-Value | Variance | SE | Z | P-Value | Variance | SD | Z | P-Value | ||||
Variance of the intercept at the regional level | 0.39 | 0.12 | 3.26 | 0.0005 | 0.35 | 0.11 | 3.26 | 0.0006 | 0.27 | 0.10 | 2.55 | 0.0054 | 0.20 | 0.09 | 2.29 | 0.0111 | ||||
Variance of the intercept at the pharmacy level | 65.48 | 0.73 | 90.21 | <.0001 | 61.92 | 0.69 | 90.23 | <.0001 | 65.44 | 0.73 | 90.24 | <.0001 | 61.85 | 0.69 | 90.28 | <.0001 | ||||
ICC | 0.0059 | 0.0055 | 0.0040 | 0.0032 |